FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

7 letters match. Newest first.

  1. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  2. Guangdong Renhe Guozhuang Biotechnology Co., Ltd.

    FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.

    High risk
  3. MedOffice Saglik Endustri Anonim Sirketi

    FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.

    High risk
  4. Deqing Jiarou Daily Chemical Co., Ltd.

    Deqing Jiarou failed current good manufacturing practice (CGMP) for OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  5. Chemical Services Group, Inc./Royal Chemical Company

    Royal Chemical Company made OTC hand sanitizer on equipment shared with industrial chemicals, and FDA found cleaning, supplier testing and quality unit failures.

    High risk
  6. Skyless, LLC

    FDA cited Skyless, LLC for CGMP failures and for selling three X-PASMO topical analgesic ointments as unapproved and misbranded drugs.

    High risk
  7. Cosmo Bio Co., Ltd.

    FDA cited South Korea's Cosmo Bio for CGMP failures and for selling an unapproved, misbranded acne drug serum in the U.S.

    High risk